OCX OncoCyte Corp

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: OCX

Price (delayed)

$3.345

Market cap

$44.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.08

Enterprise value

$40.76M

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical ...

Highlights
OCX's gross margin has surged by 176% year-on-year but it is down by 20% since the previous quarter
The revenue has soared by 58% YoY but it has decreased by 8% QoQ
OncoCyte's equity has shrunk by 69% YoY and by 43% QoQ
OCX's quick ratio is down by 47% year-on-year and by 45% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.oncocyte.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of OCX
Market
Shares outstanding
13.36M
Market cap
$44.7M
Enterprise value
$40.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.38
Price to sales (P/S)
20
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.49
Earnings
Revenue
$1.38M
EBIT
-$40.09M
EBITDA
-$38.55M
Free cash flow
-$17.43M
Per share
EPS
-$5.08
Free cash flow per share
-$2.11
Book value per share
$1.4
Revenue per share
$0.17
TBVPS
$1.74
Balance sheet
Total assets
$70.97M
Total liabilities
$54.05M
Debt
$3.34M
Equity
$11.59M
Working capital
-$1.79M
Liquidity
Debt to equity
0.29
Current ratio
0.78
Quick ratio
0.89
Net debt/EBITDA
0.1
Margins
EBITDA margin
-2,789.4%
Gross margin
22.1%
Net margin
-2,905.1%
Operating margin
-2,912.7%
Efficiency
Return on assets
-51.9%
Return on equity
-144.4%
Return on invested capital
-954.6%
Return on capital employed
-64%
Return on sales
-2,901%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCX stock price

How has the OncoCyte stock price performed over time
Intraday
-0.45%
1 week
4.21%
1 month
26.7%
1 year
-18.61%
YTD
33.8%
QTD
13.39%

Financial performance

How have OncoCyte's revenue and profit performed over time
Revenue
$1.38M
Gross profit
$305,000
Operating income
-$40.25M
Net income
-$40.15M
Gross margin
22.1%
Net margin
-2,905.1%
The operating margin has shrunk by 179% YoY and by 74% QoQ
OCX's gross margin has surged by 176% year-on-year but it is down by 20% since the previous quarter
The operating income has dropped by 60% since the previous quarter
The revenue has soared by 58% YoY but it has decreased by 8% QoQ

Growth

What is OncoCyte's growth rate over time

Valuation

What is OncoCyte stock price valuation
P/E
N/A
P/B
2.38
P/S
20
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.49
The company's EPS has surged by 53% YoY but it fell by 35% QoQ
The stock's price to book (P/B) is 98% more than its last 4 quarters average of 1.2 but 8% less than its 5-year quarterly average of 2.6
OncoCyte's equity has shrunk by 69% YoY and by 43% QoQ
The revenue has soared by 58% YoY but it has decreased by 8% QoQ

Efficiency

How efficient is OncoCyte business performance
OCX's ROIC has dropped by 82% since the previous quarter and by 15% year-on-year
The company's return on equity has shrunk by 75% QoQ and by 38% YoY
The company's return on sales has surged by 58% YoY but it has shrunk by 57% QoQ
OCX's return on assets is down by 47% since the previous quarter and by 9% year-on-year

Dividends

What is OCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCX.

Financial health

How did OncoCyte financials performed over time
OCX's total assets is 31% greater than its total liabilities
The current ratio has plunged by 53% YoY and by 48% from the previous quarter
OCX's quick ratio is down by 47% year-on-year and by 45% since the previous quarter
OCX's debt is 71% smaller than its equity
The debt to equity has surged by 107% since the previous quarter
OncoCyte's equity has shrunk by 69% YoY and by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.